Wolf-Safco SA
Wolf-Safco reported total assets of €1.25m at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Wolf-Safco shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +262 % Total assets +217 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Wolf-Safco's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 31 Aug 2024
- Year ended 31 Dec 2022filed on 16 Jun 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
Wolf-Safco's financial analysis
- Solvency98.1%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Wolf-Safco
Wolf-Safco's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0403.097.257
- VAT number
- BE0403097257
- Peppol
- Registered · 0208:0403097257 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 13 Oct 1952
- Registered office
- 3090 Overijse
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Wolf-Safco (SA) has been based in Overijse since 1952, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 13,404 € and equity of €1.23m; its revenue is not published. Its solvency stands at 98.1%, above the median of its sector (46.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Wolf-Safco
Companies in the same business, of comparable size and area, outside its group.
- Almirall Wholesale of pharmaceutical and medical goods Zaventem · balance sheet €7.75m
- Elekta Wholesale of pharmaceutical and medical goods Zaventem · balance sheet €13.1m
- Med Concept Europe Wholesale of pharmaceutical and medical goods Woluwe-Saint-Pierre · balance sheet €18.7m
- SPGL Ltd Wholesale of pharmaceutical and medical goods · balance sheet €1.01m
- O&M Halyard Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €45.9m
- sandoz Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €55.3m
- Gilead Sciences Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €68.7m
- Merck Wholesale of pharmaceutical and medical goods Hoeilaart · balance sheet €26.6m
Frequently asked questions about Wolf-Safco
What is the revenue of Wolf-Safco?
Wolf-Safco files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Wolf-Safco?
In Belgium, the VAT number is the company number prefixed with BE: BE0403097257 for Wolf-Safco, if the company is VAT-registered. Its company number (CBE) is 0403.097.257.
Where is the registered office of Wolf-Safco?
According to the CBE register, the registered office of Wolf-Safco is in 3090 Overijse.
What is the equity of Wolf-Safco?
At the close of the 2025 financial year, the equity of Wolf-Safco amounts to 1,225,080 €, a solvency of 98.1% of total assets.
Who manages Wolf-Safco?
The register lists 6 active mandates at Wolf-Safco. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Wolf-Safco
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →